Long-term ADT impaired PSMA expression in the vast majority of the primary tumor sites as well as the metastases, resulting in a relevant underestimation of the patient’s tumor burden, especially in the metastatic sites and in lower tumor stages in the majority of patients. This evidence concerns the gene FOLH1 and neoplasm.